Limits...
Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.

Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J - Cancer Sci. (2014)

Bottom Line: Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05).Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026).It can act as a worse prognostic factor for LARC patients.

View Article: PubMed Central - PubMed

Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.

Show MeSH

Related in: MedlinePlus

Fluorescence in situ hybridization in rectal cancer cells. (a) Tumors showed no HER-2 amplification. (b) Tumors showed HER-2 amplification with a HER-2/CEP17 ratio >2.0. Magnification, ×400.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317932&req=5

fig02: Fluorescence in situ hybridization in rectal cancer cells. (a) Tumors showed no HER-2 amplification. (b) Tumors showed HER-2 amplification with a HER-2/CEP17 ratio >2.0. Magnification, ×400.

Mentions: There were 31 (26.0%) cases of the 119 investigated rectal tumors classified as IHC score 0, 29 (24.4%) cases classified as IHC score 1+, 42 (35.3%) cases classified as IHC score 2+, and 17 (14.3%) cases classified as IHC score 3+ (Fig. 1). Amplification of the HER-2 gene was detected in 5% (3/60) of IHC 0–1, 12% (5/42) of IHC 2+, and 94% (16/17) of IHC 3+ samples (Fig. 2).


Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.

Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J - Cancer Sci. (2014)

Fluorescence in situ hybridization in rectal cancer cells. (a) Tumors showed no HER-2 amplification. (b) Tumors showed HER-2 amplification with a HER-2/CEP17 ratio >2.0. Magnification, ×400.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317932&req=5

fig02: Fluorescence in situ hybridization in rectal cancer cells. (a) Tumors showed no HER-2 amplification. (b) Tumors showed HER-2 amplification with a HER-2/CEP17 ratio >2.0. Magnification, ×400.
Mentions: There were 31 (26.0%) cases of the 119 investigated rectal tumors classified as IHC score 0, 29 (24.4%) cases classified as IHC score 1+, 42 (35.3%) cases classified as IHC score 2+, and 17 (14.3%) cases classified as IHC score 3+ (Fig. 1). Amplification of the HER-2 gene was detected in 5% (3/60) of IHC 0–1, 12% (5/42) of IHC 2+, and 94% (16/17) of IHC 3+ samples (Fig. 2).

Bottom Line: Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05).Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026).It can act as a worse prognostic factor for LARC patients.

View Article: PubMed Central - PubMed

Affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.

Show MeSH
Related in: MedlinePlus